study question: Is the pain associated with levonorgestrel-releasing intrauterine system (LNG-IUS) insertion reduced by intracervical anesthesia in women without previous vaginal birth? summary answer: Intracervical anesthesia was not associated with reduced pain in women without previous vaginal birth. what is known already: The pain associated with the insertion of intrauterine contraceptives (IUCs) is a limiting factor for the use of these contraceptives by some women. No prophylactic pharmacological intervention has proven efficacy in relieving pain during or after the insertion of IUCs. However, previous studies included women with previous vaginal delivery, and injectable intracervical anesthesia was not evaluated in any of these studies. study design, size, duration: This was a randomized, open, parallel-group clinical trial that evaluated 100 women without previous vaginal delivery who wished to use the LNG-IUS for the first time. These women were evaluated immediately after LNG-IUS insertion and then 2 h and 6 h later.
Introduction
The levonorgestrel-releasing intrauterine system (LNG-IUS) is a longacting reversible contraceptive with a 0.2% failure rate, high continuation rate at 1 year (80%), and a rapid return of fertility when removed (Grimes, 2009; Mansour et al., 2011; Trussell, 2011) . In addition to the high contraceptive efficacy, the LNG-IUS presents non-contraceptive benefits, such as reduced menstrual bleeding and decreased dysmenorrhea, which benefits women with endometriosis, adenomyosis and heavy menstrual bleeding (Shimoni, 2010; Heikinheimo et al., 2012) . LNG-IUS use in adolescents and nulliparous women presents more benefits than risks (WHO, 2009) . After appropriate contraceptive counseling, the acceptability of the LNG-IUS is high, and it is safe and extremely effective in nulliparous women (ACOG, 2007; Prager and Darney, 2007; Lyus et al., 2010; Bahamondes et al., 2011; Marions et al., 2011; Winner et al., 2012; Aoun et al., 2014) .
One of the main reasons limiting the use of intrauterine contraceptives (IUCs) is the fear of pain on the part of women and the difficulty of inserting the device on the part of healthcare professionals, which is more common in nulliparous women and in those with no previous vaginal deliveries (Suhonen et al., 2004; Lyus et al., 2010; Santos et al., 2013) . Most IUC insertions do not require pain control; however, a proportion of nulliparous (17%) and multiparous (11%) women experience significant pain and will require active pain management (Heikinheimo et al., 2010; Marions et al., 2011) .
No prophylactic pharmacological intervention has proven efficacy in relieving pain during or after the insertion of IUCs (Allen et al., 2009; Gemzell-Danielsson et al., 2013) . The available studies assessing the ease of insertion and the pain reported by IUCs users have investigated the effects of misoprostol, non-steroidal anti-inflammatory drugs (NSAIDs) either alone or combined with misoprostol, and local anesthesia (gel or a paracervical block) (Hubacher et al., 2006; Saav et al., 2007; Chor et al., 2012; Karabayirli et al., 2012; McNicholas et al., 2012; Mody et al., 2012; Swenson et al., 2012; Allen et al., 2013; Lathrop et al., 2013; Nelson and Fong, 2013; Espey et al., 2014) . Furthermore, anxiety and fear prior to the procedure may contribute to increased pain; therefore, adequate counseling prior to IUC insertion is crucial (Murty, 2003; Gemzell-Danielsson et al., 2013) .
There are no RCTs evaluating pain scores and the ease of LNG-IUS insertion when injectable intracervical anesthesia is used prior to insertion, which could increase the use of this contraceptive method by women who are afraid of having pain or discomfort with the insertion of an IUC. Thus, the primary aim of our study was to evaluate the effect of intracervical anesthesia compared with NSAIDs on pain scores immediately following LNG-IUS insertion in women without a previous vaginal delivery who had not previously used any IUC. The secondary objectives were to evaluate the effects of the interventions on pain scores assessed 2 and 6 h after LNG-IUS placement, on the level of discomfort associated with the insertion procedure, and on the ease of LNG-IUS insertion.
Methods
This study was a randomized, open, parallel-group clinical trial conducted at the Clinics Hospital of the Medical School of Ribeirao Preto, University of Sao Paulo (Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo-HC-FMRP-USP), Brazil. The trial was registered at ClinicalTrials.gov (www.clinicaltrials.gov; NCT02155166).
The inclusion criteria were patients who had not previously used an IUC and wanted to use the LNG-IUS (daily release of 20 mg of LNG) for the first time as a contraceptive, age between 18 and 45 years, and nulliparity or no previous vaginal delivery. The exclusion criteria were women in categories 3 and/or 4 for LNG-IUS use according to the medical eligibility criteria of the World Health Organization (WHO) (WHO, 2009), illicit drug and/or alcohol users, women with allergies or contraindications to NSAIDs or lidocaine, acute or chronic pelvic pain of any etiology, abnormalities of the cervix (such as fibrosis or isthmus-cervical incompetence), previous abortion/miscarriage with or without uterine curettage, psychiatric disorders, and continued use of medications that could interfere with pain threshold.
Women who wanted to use the LNG-IUS were selected through written media advertisements. The volunteers who wanted this contraceptive method visited the outpatient contraception service of the HC-FMRP-USP and, after their eligibility criteria were verified, were consecutively enrolled in the study.
Because psychiatric disorders were considered an exclusion criterion, each patient completed a questionnaire on depression and anxiety [Hospital Anxiety and Depression Scale (HAD)] that has been validated in Brazil (Botega et al., 1995) . Volunteers with scores compatible with depression (.9 points) or anxiety behaviors (.8 points) were excluded from the study.
In total, 100 women who had not previously used an IUC were randomized to 400 mg of ibuprofen or 1.8 ml of 2% lidocaine. Women were enrolled from February 2012 to July 2013. The first group received 400 mg of ibuprofen, an NSAID, 1 h prior to LNG-IUS insertion. Ibuprofen was chosen because previous studies have demonstrated that its effect on pain associated with IUC insertion is similar to placebo (Hubacher et al., 2006; Chor et al., 2012) . In the second group, 2% lidocaine without a vasoconstrictor (injectable local anesthetic) was applied into the cervix at the 3-, 6-, 9-and 12-o'clock positions using a carpule syringe and a 27-gauge needle. The content of the anesthetic cartridge (1.8 ml) was equally divided among the four injection sites (Fig. 1) . A 5-min interval was standardized between the completion of the anesthetic injection and the beginning of the LNG-IUS insertion. The device was inserted between Day 1 and Day 5 of the menstrual cycle using the usual technique recommended by the manufacturer.
Using block randomization, the women were allocated into two intervention groups by computer software (www.randomizer.org) in a 1:1 allocation ratio with a block size of four patients. The randomized groups were stored in sealed envelopes by one of the investigators (CSV) and only opened by the investigator (TVBC) who performed the intervention at the time of the study. The randomized allocation sequence was generated by CSV, and the inclusion of the study participants was conducted by TVBC and SAF.
As the primary aim, the effect of injectable intracervical anesthesia was compared with NSAID use in controlling the pain associated with LNG-IUS insertion in women without previous vaginal delivery. The pain was evaluated immediately and then 2 and 6 h after LNG-IUS insertion using two scales: the visual analogue scale (VAS) and the facial pain scale (Ministério da Saúde do Brasil, 2003) . The VAS was measured with a 100-mm straight line, with the starting point (0) meaning no pain and the end point (100) meaning the worst pain that the woman could imagine. The same scale was also qualitatively analyzed (0-30 mm: mild pain, 40 -60 mm: moderate pain and 70 -100 mm: severe pain). As secondary aims, the overall experience with the LNG-IUS insertion (classified according to the patient as slightly uncomfortable, uncomfortable or very uncomfortable) and the ease of inserting the LNG-IUS (as rated by the provider as easy or difficult) were also analyzed. Only one trained LNG-IUS inserter was responsible for the insertions in this study (TVBC) .
Thirty days after the insertion, the patients returned, and a transvaginal ultrasound examination was performed to evaluate the LNG-IUS.
To determine the sample size, a pilot study including six women in each group was conducted to evaluate the mean and standard deviation of the pain associated with LNG-IUS insertion. In the pilot study, the mean pain level (assessed by a VAS) when ibuprofen was used was 68 + 11 mm, and the mean pain level when the injectable intracervical anesthetic was used was 28 + 10 mm (P ¼ 0.02, linear mixed-effects model). Thus, considering a 10% difference between the treatments to achieve clinical relevance, 40 women per group would be required, with an alpha of 5% and a test power of 80%. In total, 100 women were included, considering the possibility of sample loss and protocol violation with the use of analgesic medications after LNG-IUS placement.
The statistical analysis was blind. All of the women signed a free and informed consent form, and the study was approved by the ethics committee of our hospital.
The chi-squared test was used for the qualitative variables, and Student's t-test was used for the normally distributed quantitative variables. A linear mixed-effects model was used to evaluate the paired variables. Finally, to assess the predictor of moderate/severe pain (response variable), a logistic regression was performed with the presence of a previous Cesarean delivery, years of education (quantitative), and the intervention group for pain (NSAID or anesthetic) as covariates. For all data comparisons, the SAS w 9.0 software (SAS Institute, Inc., Cary, NC, USA) was used. The level of significance was set at 5%. There were no missing data; therefore, data imputation was not necessary.
Results
Of the 158 women who wanted to use the LNG-IUS, 30 women did not meet the inclusion criteria (25 had a previous vaginal delivery and 5 were older than 45 years), and 28 women met the exclusion criteria: 12 had a history of chronic pelvic pain, 10 had a previous miscarriage, 5 were using medications that would reduce pain threshold, and 1 presented with acute pelvic inflammatory disease. None of the patients presented HAD scale scores indicating depression and/or anxiety. In total, 100 women were randomized, with 50 included in the NSAID group and 50 in the anesthetic group. There were two dropouts in the NSAID group, which consequently had 48 volunteers in total. The selected women were assessed immediately after LNG-IUS insertion and then 2 and 6 h after insertion. At the evaluation performed 30 days after the procedure, four cases of device expulsion were found, with two expulsions from each group (Fig. 2) .
The clinical variables were similar between the groups (Table I) . Pain (assessed by both scales), the level of discomfort associated with LNG-IUS insertion and the difficulty of the LNG-IUS insertion did not differ between the groups (Table II) . The difference between the mean pain level assessed by the VAS in the intracervical anesthesia group and in the NSAID group was ,10%. Approximately 50% of the sample from both groups classified the LNG-IUS insertion experience as slightly uncomfortable. Cervical dilation was required in the patients with difficult insertions.
The multivariate assessment of the predictors of moderate/severe pain showed that being nulliparous was the variable most associated with moderate/severe pain [adjusted odds ratio (OR): 3.1 (95% confidence CI: 1.3-7.8)], increasing the risk of moderate/severe pain three times. Intracervical anesthesia reduced the risk of moderate/severe pain by 40% [adjusted OR: 0.6 (95% CI: 0.2 -1.4)] but without statistical significance (Table III) . The number of years of formal education was not associated with moderate/severe pain.
Discussion
The main finding of this study was that the pain measured by two different pain scales (the VAS and the facial pain scale) was not different when an injectable intracervical anesthetic or NSAID was used in nulliparous women or in those without previous vaginal delivery. Multivariate analysis demonstrated that being nulliparous increased the risk of a woman presenting moderate/severe pain 3-fold, while the use of local anesthesia reduced the pain by 40% compared with the use of an NSAID, although the reduction was not statistically significant.
Analgesic drugs (such as NSAIDs), misoprostol (for cervical priming) and local anesthesia have been evaluated in previous studies addressing interventions to relieve the pain associated with IUC insertion (Allen et al., 2009; Gemzell-Danielsson et al., 2013) . With the exception of one study (Karabayirli et al., 2012) , NSAIDs are not reported to be more effective than a placebo in relieving the pain associated with IUC insertion (Hubacher et al., 2006; Chor et al., 2012) ; therefore, their routine use is not recommended in this procedure. All of the studies that evaluated Only one previous study evaluated the effect of a paracervical block (Mody et al., 2012) . Comparing that study to the present study, we used an intracervical block with a carpule syringe and a 27-gauge needle, which is thinner than is commonly used for paracervical blocks, but in the Mody et al. (2012) study, there is no mention of which syringe was used. Another difference is that we used only one type of IUC (the LNG-IUS), and only women without a previous vaginal delivery were randomized. In the Mody et al. (2012) study, two types of IUCs were used, and 65% of the women were multiparous, without evaluation of the type of previous delivery.
One limitation of our study was the fact that an injection of a local anesthetic was compared with an oral medication. Intracervical injection of a saline solution (or even a dry needling) as the placebo for a double-blind study could be a more adequate control. However, this approach was not allowed by our institutional review board because the needle could produce more pain than not using any medication, which is the standard technique for IUC insertion. An NSAID was chosen as the control because the vast majority of previous studies using this medication for the insertion of IUCs showed that an NSAID's effect on the pain associated with IUC insertion was similar to a placebo (Hubacher et al., 2006; Chor et al., 2012) . Another control option would have been to have left one group without intervention, but there were concerns that a volunteer randomized to the group without an intervention might have had her pain perception negatively influenced by the absence of a potentially beneficial intervention.
Another limitation could be the absence of pain evaluation for the tenaculum placement because the intracervical anesthesia is likely to have an effect on this procedure. However, it could potentially be artificial to separate the whole IUS insertion procedure into two steps (tenaculum Twelve subjects presented chronic pelvic pain, 10 had a previous abortion, 5 were using medications that reduce the pain threshold, and 1 presented acute pelvic inflammatory disease. NSAID, non-steroidal anti-inflammatory drug. placement and IUS insertion). In a clinical scenario, health providers need to know if the whole IUS insertion procedure would be less uncomfortable or less painful with the intervention. If the intervention does not prove to affect the whole procedure, the importance of altering the pain during tenaculum placement is questionable. Furthermore, after tenaculum placement, there is some residual pain, and the evaluation of the absolute VAS score associated with the IUC insertion could be biased. This study's findings can be generalized to most insertions in nulliparous women or in women without a previous vaginal delivery, considering that the majority of the insertions were easy (.80% in both groups), similar to the rates found in a previous study (Bahamondes et al., 2011) . In difficult insertions that require cervical dilatation, the effect of the tested intervention might be different. Considering that ,20% of the sample experienced a difficult insertion, the current study could not perform this evaluation because of lack of power.
Although most patients reported mild to moderate pain with LNG-IUS insertion, the discomfort of the procedure assessment revealed that 50% of women classified the procedure as slightly uncomfortable. The level of discomfort did not differ between the groups.
Regarding the IUC insertion, a previous study evaluated the difficulty of LNG-IUS insertion in groups of nulliparous and multiparous women, with the insertion being classified as either easy or difficult (use of dilators, misoprostol or insertion failure). In 80% of cases, the insertions were classified as easy by the inserter. However, the insertions classified as difficult were three times greater in the group of nulliparous women (Bahamondes et al., 2011) . Studies evaluating the effect of misoprostol (alone or associated with NSAIDs) on the pain from and the ease of insertion of an IUC revealed no improvement in pain, and this medication did not facilitate insertion (Swenson et al., 2012; Espey et al., 2014) , with the exception of one study that concluded that misoprostol facilitated insertion (Saav et al., 2007) . Studies on the use of NSAIDs alone assessed only the pain during the procedure but not the difficulty of insertion (Hubacher et al., 2006; Chor et al., 2012; Karabayirli et al., 2012) . Similarly, studies using a local anesthetic (gel or paracervical block) in the cervix did not include the level of difficulty of the IUC insertion (McNicholas et al., 2012; Mody et al., 2012; Allen et al., 2013; Nelson and Fong, 2013) . Anxiety associated with the IUD insertion procedure may compromise pain scores (Murty, 2003; Gemzell-Danielsson et al., 2013) , but in our study, women with anxiety disorders and depression were excluded. Moreover, a depression and anxiety score was applied to exclude those women without a diagnosis but with anxiety/depression traits that could produce bias in our findings.
A strength of the current study was the pain assessment using two different scores (the VAS and the facial pain scale), which was unique in relation to all previous studies that assessed pain scores during IUC insertion using only an analogue pain scale. Although pain is a universal experience, its perception is subjective and subject to considerable variability. This fact is important and should be taken into account in designing clinical trials. Several measures can be taken to ensure a careful and reproducible measurement of pain. One is the use of two independent scales that are easily and widely used (Farrar, 2010) . The agreement of pain evaluation results from two different scales (VAS and facial pain scale) supports our results indicating moderate pain with LNG-IUS insertion.
In conclusion, the use of an injectable intracervical anesthetic is not associated with pain relief, change in discomfort level, or ease of insertion of LNG-IUS compared with NSAID use in women without previous vaginal birth. Because nulliparous women presented a greater risk of pain and because the anesthetic reduced the risk of moderate/severe pain by 40%, assessments of only nulliparous or women with difficult insertions are required in future studies.
